Hello JKR12 and All,
If you elect to use Warfarin/Coumadin this is a device for home checking INR that my wife is going to get … only requires a drop of blood.
http://www.coaguchek-usa.com/coaguchek_hcp/en_US/home/coaguchek-products/coaguchek-xs-system.html
(these units are available on eBay and other resale locations if not covered by insurance.)
She elected to stay with Warfarin since an antidote to stop bleeding is readily available if she is in a crash or gets wounded and also Warfarin has been around for many years and has a track record …
Currently she gets INR checked about every 2 weeks and shoots for about 2.0 with the recommended range 2.0 to 3.0.
If she gets a bruise it will last a few days but at 2.0 has no underskin bleeds and no other noticeable affects.
She is quite sensitive to diet changing the INR reading … and also antibiotics and other meds affect it … and regards diet as not a problem but just something to be aware of … perhaps requiring a small change in Warfarin dosage.
There is information about Xarelto and Eliquis lawsuits on Google … for instance:
https://www.fiercepharma.com/pharma/judge-tosses-lawsuit-against-pfizer-bms-over-eliquis-bleeding-risks
"A judge in New York tossed liability claims against Pfizer and Bristol-Myers Squibb over bleeding risks for their blockbuster anticoagulant on Monday, ruling that the drugmakers and U.S. drug regulators clearly presented Eliquis’ risks to patients and doctors.
Plaintiffs Charlie and Ciara Utts brought the case against the companies last year, claiming that the big-selling Eliquis caused Charlie to experience severe gastrointestinal bleeding. Further, the plaintiffs said the drug’s label didn’t adequately warn of the risks.
But that’s not true, U.S. District Judge Denise Cote wrote in an opinion filed Monday.
Eliquis’ risks, plus the known lack of an antidote, “were clearly disclosed to the Food & Drug Administration when it approved the drug, and are prominently disclosed to medical practitioners and patients on the FDA-approved labeling for the drug,†Cote wrote in her 85-page opinion.
In their suit, the plaintiffs also contend the label is flawed because dosage recommendations aren’t individually tailored for patients and because it doesn’t recommend constant monitoring, according to the judge. Cote said those claims “fare no better†under scrutiny."